Interleukin 12: still a promising candidate for tumor immunotherapy?
Open accessThe DOI matches its Crossref record; 362 of the 362 references it cites were found in a registry or an index.
Abstract
Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities. However, despite encouraging results in animal models, very modest antitumor effects of IL-12 in early clinical trials, often accompanied by unacceptable levels of adverse events, markedly dampened hopes of the successful use of this cytokine in cancer patients. Recently, several clinical studies have been initiated in which IL-12 is applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). The near future will show whether this renewed interest in the use of IL-12 in oncology will result in meaningful therapeutic effects in a select group of cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous attempts to develop IL-12-based therapies for human use had severely toxic consequences (Lasek et al., 2014) likely due to systemic administration routes.”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Lasek et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5 retracted
(1999) · The FASEB Journal · doi:10.1096/fasebj.13.12.1575 · Cited by 152 · cited 1×
“[85], and TNF-mediated apoptosis of fibroblasts [86].”
RetractedThe IL-15Rα Chain Signals Through Association with Syk in Human B Cells
Bulanova, E., Budagian, V., Pohl, T., Krause, H., Dürkop, H., Paus, R., & Bulfone-Paus, S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6292 · Cited by 84 · cited 2×
“and dendritic cells in particular, simultaneously express the IL15Ra chain, which, in contrast to IL-2Ra, binds IL-15 with high affinity (Ka 10 11 M) [43] and can mediate signal transduction [44].”
BackgroundRetractedA promiscuous liaison between IL‐15 receptor and Axl receptor tyrosine kinase in cell death control
Budagian, V., Bulanova, E., Orinska, Z., Thon, L., Mamat, U., Bellosta, P., Basilico, C., Adam, D., Paus, R., & Bulfone‐Paus, S. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600874 · Cited by 75 · cited 2×
“On the other hand, both the IL-2/15b chain and a unique IL-15Ra chain signal through SYK protein tyrosine kinase of the SYK/ZAP-70 family [44,69], and IL-15Ra activates protein tyrosine kinase AXL [70].”
BackgroundRetractedBulanova, E., Budagian, V., Duitman, E., Orinska, Z., Krause, H., Rückert, R., Reiling, N., & Bulfone-Paus, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610036200 · Cited by 63 · cited 2×
“On the other hand, some soluble IL-15Ra isoforms released as a result of alternative splicing or proteolytic cleavage [57] could inhibit the activity of IL-15 [57,58], and tumor cells can release proteolytically cleaved IL-15Ra as one of their tumor evasion strategies [59].”
BackgroundRetractedReverse Signaling through Membrane-bound Interleukin-15
Budagian, V., Bulanova, E., Orinska, Z., Pohl, T., Borden, E. C., Silverman, R. H., & Bulfone‐Paus, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403182200 · Cited by 60
RetractedChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“In contrast to mice, human tumors seem to consist of much more heterogenous population of tumor cells, developed as a result of tumor escape mechanisms, and contain strongly immunosuppressive soluble and cellular components (including myeloid-derived suppressor cells) that are resistant to IL-12-induced antitumor acti…”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundDevelopment of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134 · cited 1×
“The main source of IL-12 in humans is the activated antigen-presenting cells, such as dendritic cells [4], especially of the CD1c+ phenotype [5], as well as the hematopoietic phagocytes (monocytes, macrophages, and also neutrophils) [6], but IL-12 can also be produced by other cell types [7, 8].”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Cited by
Items 501–550 of 550
Zhang, J., Wang, L., Li, S., Gao, X., & Liu, Z. (2022) · Figshare · doi:10.6084/m9.figshare.20098381
Injectable Controlled Delivery Immunotherapies for the Treatment of Melanoma
Hwang, M. P. (2019) · eCommons (Cornell University) · doi:10.7298/50qt-dn18
Natural Killer cell immune engagers to induce optimal anti-tumor activity.
Chiu, E. (2021) · University of Minnesota Digital Conservancy (University of Minnesota)
Brišar, N. (2024) · Repository of the University of Ljubljana (University of Ljubljana)
Impacto dos polimorfismos de citocinas no desenvolvimento do Adenocarcinoma Colo-Retal
Fernandes, S. M. M. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Jacobs, L. (2021) · Lirias (KU Leuven)
Mohamed Amin, Z. (2019) · Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia)
Characterizing a MUC4-Based Nanovaccine and Enhancing its Efficacy by Targeting the Endothelin Axis
Gulati, M. (2022) · DigitalCommons@UNMC
Identifizierung von Regulatoren der Tumorgefäßmorphologie
Hoffmann, H. (2016)
Biophysical Enhancement of Protein Therapeutics and Diagnostics Through Engineered Linkers
Long, N. E. (2018) · OhioLink ETD Center (Ohio Library and Information Network)
Locally Administered Particle-Anchored Cytokines Safely Enhance Cancer Immunotherapy
Niu, L. (2024) · VTechWorks (Virginia Tech)
Targeted activation of dendritic cells via the CD40 receptor
Wingham, B. (2018) · Repository@Hull (Worktribe) (University of Hull)
Understanding the tumor microenvironment in glioblastoma for the development of focused therapies
Nieland, L. (2025) · Leiden Repository (Leiden University)
Lamprecht, R. (2021) · OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg)
Caractérisation des rôles de CLCF1 dans la biologie de l’IL-12
Laplante, V. (2025) · doi:10.71781/32656
Zhang, Y., Qiang, R., Ding, M., & Wang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1723844
“The growing fi eld of immune-based therapies, which aim to enhance CTL-mediated tumor cell killing by targeting the TME, has shown promising results in various human malignancies (39, 40).”
da Silva, A. P. D. B. C. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Expression of programmed cell death ligand 1 (PDL1) in uveal melanoma
Velez, J. P. Z. (2018) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Saeed, A. Z., & Darweesh, M. F. (2025) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_563_23
Zhang, W., Ming, L., & Fang, D. (2023) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/0qcikhjaqh
Yang, J., Chen, S. S., Idnani, E., Shannon, S. R., Luly, K. M., Fabilane, C. S., Wilson, D. S., Spangler, J. B., Tzeng, S. Y., & Green, J. J. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201708
“25 For this study, two doses were tested: 3 ng/kg and 500 ng/kg, the latter of which was the MTD observed in humans.”
Schlatter, J. N., Wei, W., Chen, Y., Melse, A., Wang, Y., Guerra, S., & Oberholzer, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1755796
“The systemic distribution of the cytokine tends to yield strong off-target effects with systemic activation and proliferation of immune cells, making it dif fi cult to achieve adequate intratumoral therapeutic levels without exceeding systemic toxicity thresholds (80, 99).”
InfluentialFontaine, M. B. (2017) · theses.fr (ABES) · doi:10.70675/19f021abze152z4dd1za271z715352e2629c
Immunosubversion du Lymphocyte Natural Killer par Pseudomonas aeruginosa
Vourc’h, M. (2017) · theses.fr (ABES) · doi:10.70675/108c384az4b8ez4afcza54bzb8998a6f8fe4
Rôle de Programmed cell Death-Ligand 1 dans la progression du carcinome hépatocellulaire
Rousseau, B. (2021) · theses.fr (ABES) · doi:10.70675/dd181429zd664z4681zbe04z06271b5e1f39
Gum Acacia Synthetic Routes for Anticancer Treatment Development
Bashir, T., Danish, M. A. U., Bano, F., Ijaz, T., Tang, J., & Saleem, M. A. U. (2026) · Wiley eBooks · doi:10.1002/9781394345472.ch5
Role of cytokines in cancer immunology
Madan, E., Bissa, B., Goel, A., Khan, M. S., Chandra, N., Jain, K., Tiwari, A., Soni, N., & Mandlik, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41551-7.00021-7
Interleukin-12 Gene Therapy for Cancer Immunotherapy
Jesenko, T., Tratar, U. L., Serša, G., Kamenšek, U., & Čemažar, M. (2026) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-032-24071-2_12
Advancements in cancer immunotherapy: Targeting the tumor immune microenvironment (TIME)
Sadar, S. S., Polshettiwar, S. A., Phalak, C., Walhekar, V., Chaher, S., & Lagad, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45717-3.00015-5
Gao, S., Luo, R., Dai, C., Zhang, X., Liao, B., Chen, Z., Guo, Y., Guo, M., Zhang, J., Zhang, K., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c04887
Programmable DNA origami architectures as smart therapeutics for immune regulation
Wu, Y., Tian, R., Jiang, Q., & Ding, B. (2026) · Materials Today · doi:10.1016/j.mattod.2026.103441
A Bioorthogonal Desilylation System Potentiates mRNA Therapeutics in Tumors
Zhang, M., Wang, C., Xu, X., Ding, Z., Chen, J., Guo, Z., & Liu, Z. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c09548
Nanocarriers in Ovarian Cancer: Targeted Drug Delivery, Theranostics, and Immunomodulation
Grace, S. R., Kennedy, M. M. R., & Enoch, I. V. M. V. (2026) · BioNanoScience · doi:10.1007/s12668-026-02811-2
Wang, X., Yang, L., Hou, Y., Wang, G., Ding, Y., Zhang, Y., Wang, S., & Hong, Z. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177716
Čemažar, M., Tratar, U. L., Milevoj, N., Serša, G., & Tozon, N. (2026) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.26.06.0510
Beyond CD19: Engineering next-generation CAR-T cell therapies for leukemia
Singh, T., Jain, A., Bohot, M., Tuli, H. S., Banerjee, S., Barbalho, S. M., Direito, R., Casarcia, N., & Bishayee, A. (2026) · Current Molecular Pharmacology · doi:10.1016/j.cmp.2026.09.006
Omata, D., Munakata, L., Yoshioka, Y., & Suzuki, R. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108963
Interleukin‐12: Central Roles in Immune Regulation and Disease Therapy
Psoma, A., & van den Bogaart, G. (2026) · Immunology and Cell Biology · doi:10.1111/imcb.70167
Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer
Anwer, K., Sood, S., Sparks, J., Faller, D. V., Limon, A. E., & Lindborg, S. R. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101250
The expression window as a safety parameter for mRNA medicines
Tani, H. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118513
Traineeship Reports and Monograph titled "Oncolytic viruses the new approach on cancer therapy"
Matias, B. D. G. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Bioengineered tumour-targeted cytokines for tolerable immunotherapy combinations in solid tumours.
Herpels, M. (2024) · Spiral (Imperial College London) · doi:10.25560/150966
Remic, T., Sersa, G., Levpuscek, K., Tratar, U. L., Valentinuzzi, K. U., Cör, A., & Kamensek, U. (2022) · doi:10.3389/fimmu.2022.974912.s001
Cini, J. K., Dexter, S., Rezac, D. J., McAndrew, S. J., Hedou, G., Brody, R., Eraslan, R.-N., Kenney, R. T., & Mohan, P. (2023) · doi:10.3389/fimmu.2023.1326927.s001
Seaver, K., Kourko, O., Gee, K., Greer, P. A., & Basta, S. (2022) · doi:10.3389/fimmu.2022.884827.s003
Metadata
- Authors
- Lasek, W., Zagożdżon, R., & Jakobisiak, M.
- Affiliations
- Medical University of Warsaw (PL)
- Corresponding author
- Lasek, Witold
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2014-02-11
- Volume
- 63
- Issue
- 5
- Pages
- 419-435
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC3994286
- OpenAlex
- W2025459290
- Cited by
- 495
- References
- 354
- Citations by year
- 2026: 23 · 2025: 40 · 2024: 42 · 2023: 49 · 2022: 52 · 2021: 53 · 2020: 64 · 2019: 41 · 2018: 33 · 2017: 32 · 2016: 33 · 2015: 21 · 2014: 7
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Commission (316254)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- IL-12, cancer immunotherapy, cancer vaccines, gene therapy, immunocytokines, natural killer cells, cytotoxic T lymphocytes, antitumor immunity
- MeSH terms
- Animals, Humans, Immunotherapy, Neoplasms, Genetic Therapy, Interleukin-12, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.